ESMO 2019 | PAOLA-1 Phase 3 data: olaparib plus bevacizumab maintenance for advanced ovarian cancer
Isabelle Ray-Coquard, MD, PhD, of Léon Bérard Center, Lyon, France, discusses the phase 3 PAOLA-1/ENGOT-ov25 trial (NCT02477644) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Prof. Ray-Coquard highlights data from the trial regarding the use of olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed advanced ovarian cancer treated with platinum- based chemotherapy plus bevacizumab. Susana Banerjee, MBBS, PhD, FRCP, of the Royal Marsden NHS Foundation Trust, London, UK, then provides an insightful commentary.
Get great new content delivered to your inboxSign up